Low-density lipoprotein apheresis in the prevention of recurrent coronary heart disease: A review

Therapeutic Apheresis

Volumn 7, Issue 4, 2003, Pages 408-412

  Tasaki, Hiromi ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Atherosclerosis; Coronary heart disease; Hypercholesterolemia; LDL apheresis

Indexed keywords

LOW DENSITY LIPOPROTEIN; NITRIC OXIDE; VASOACTIVE AGENT;

ANGIOGRAPHY; APHERESIS; BLOOD RHEOLOGY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BLOOD FLOW; HUMAN; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT INDICATION;

CORONARY ARTERIOSCLEROSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPOPROTEINS, LDL; MALE; PLASMAPHERESIS; RECURRENCE; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 0041815982     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-0968.2003.00076.x     Document Type: Review

References (21)

1. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
2. LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
3. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol level. N Engl J Med 1996;335:1001-9.
4. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
5. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998;279:1615-22.
6. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001;21:1712-9.
7. Gordon BR, Kelsey SF, Dau PC et al. Treatment of refractory familial hypercholesterolemia by low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. Am J Cardiol 1998;81:407-11.
8. Mabuchi H, Koizumi J, Shimizu M et al. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am J Cardiol 1998;82:1489-95.
9. Nishimura S, Sekiguchi M, Kano T et al. Effects of intensive lowering by low-density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan Low-density Lipoprotein Apheresis Coronary Atherosclerosis Prospective Study (L-CAS). Atherosclerosis 1999;144:409-17.
10. Kroon AA, Aengevaeren WR, van der Werf T et al. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 1996;93:1826-35.
11. Horiuchi M, Tasaki H, Takatsu H et al. Effect of LDL apheresis on patients with coronary artery disease and severe hypercholesterolemia-FUKUOKA LDL apheresis STUDY. Jpn Circulation J 2000;64:642.
12. Thompson GR, Maher VM, Matthews S et al. Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis. Lancet 1995;345:811-6.
13. Egashira K, Hirooka Y, Kai H et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994;89:2519-24.
14. Treasure CB, Klein JL, Weintraub WS et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-7.
15. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995;332:488-93.
16. Baller D, Notohamiprodjo G, Gleichmann U, Holzinger J, Weise R, Lehmann J. Improvement in coronary flow reserve determined by positron emission tomography after 6 months of cholesterol-lowering therapy in patients with early stages of coronary atherosclerosis. Circulation 1999;99:2871-5.
17. Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 1997;95:76-82.
18. Schachinger V, Britten MB, Zeiger AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term out-come of coronary heart disease. Circulation 2000;101:1899-906.
19. Aengevaeren WR, Kroon AA, Stalenhoef AF, Uijen GJH, van der Werf T. Low density lipoprotein apheresis improves regional myocardial perfusion in patients with hypercholesterolemia and extensive coronary artery disease. LDL-Apheresis Atherosclerosis Regression Study (LAARS). J Am Coll Cardiol 1996;28:1696-704.
20. Mellwig KP, Baller D, Gleichmann U, Moll D, Betker S, Weise R. Notohamiprodjo. Improvement of coronary vasodilatation capacity through single LDL apheresis. Atherosclerosis 1998;139:173-8.
21. Kobayashi K, Tasaki H, Suzuka H et al. Improvement of coronary flow velocity reserve evaluated by transthoracic Doppler echocardiography after single LDL apheresis. Circulation J 2002;66:760.